What it's for (Indications)
- Olmesartan medoxomil, an angiotensin II receptor blocker (ARB), is primarily indicated for the treatment of hypertension (high blood pressure) in adult patients.
- It can be utilized as monotherapy or in conjunction with other antihypertensive agents to achieve target blood pressure goals.
- The reduction in blood pressure observed with olmesartan medoxomil is directly associated with a decrease in the risk of fatal and non-fatal cardiovascular events, including stroke and myocardial infarction.
- Furthermore, olmesartan medoxomil is also indicated for the treatment of hypertension in pediatric patients aged 6 to 16 years.
- This broad indication underscores its utility in managing elevated systemic arterial pressure across various patient demographics, aiming to prevent long-term end-organ damage associated with uncontrolled hypertension.
- Regular monitoring of blood pressure is essential to assess treatment efficacy and guide dosage adjustments as necessary, always in accordance with current clinical guidelines.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Olmesartan medoxomil tablets are taken orally, once daily, with or without food. Swallow the tablet whole; do not crush or chew it. It is recommended to take the medicine at the same time each day to aid adherence. Dosage must be individualized. For adult hypertension, the usual starting dose is 20 mg once daily. The dose may be increased to 40 mg once daily after 2 weeks if further blood pressure reduction is needed; doses above 40 mg generally do not provide greater effect. For pediatric hypertension (6 to 16 years), the starting dose for patients weighing 20 to <35 kg is 10 mg once daily (range 10 to 20 mg once daily), and for patients weighing ≥35 kg, it is 20 mg once daily (range 20 to 40 mg once daily). If blood pressure is not controlled by olmesartan medoxomil alone, a diuretic or other antihypertensive agents may be added. Store at room temperature, away from direct heat and sunlight, and keep out of the reach of children and pets. Always use exactly as instructed by your doctor. |
Safety & Warnings
Common Side Effects
- The most common adverse reaction reported is dizziness (3%).
- Other potential side effects include headache, edema (collection of body fluid in tissues and body cavities), fatigue, flushing, swollen ankles, pounding heartbeat, and lightheadedness.
- Consult a doctor if any of these symptoms persist for a prolonged period.
Serious Warnings
- Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue olmesartan medoxomil as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
- Fetal Toxicity: When pregnancy is detected, discontinue olmesartan medoxomil as soon as possible.
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
- Alcohol consumption should be avoided.
- Before starting treatment, inform your doctor about your complete medical history, especially if you have heart disease, liver disease, or pre-existing low blood pressure.
- Disclose all current medications.
- Do not discontinue this medicine without consulting your doctor.
- Use with caution in patients with intravascular volume depletion, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, primary aldosteronism, and liver impairment.
- Special caution is advised for individuals with excessively low blood pressure accompanied by ischemic heart disease or ischemic cerebrovascular disease, as this may increase the risk of myocardial infarction (MI) or stroke.
- This medicine should not be shared with others.
How it Works (Mechanism of Action)
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB). Angiotensin II, formed from angiotensin I by ACE, is the primary pressor agent of the renin-angiotensin system, mediating vasoconstriction, aldosterone stimulation, cardiac stimulation, and renal sodium reabsorption. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively binding to and blocking the AT1 receptor in vascular smooth muscle. This action is independent of angiotensin II synthesis pathways. Olmesartan has significantly higher affinity for the AT1 receptor over the AT2 receptor.